Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Total Non-Current Liabilities (2023 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $66.2 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 16.52% to $66.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $66.2 million through Dec 2025, down 16.52% year-over-year, with the annual reading at $66.2 million for FY2025, 16.52% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $66.2 million at Day One Biopharmaceuticals, up from $62.2 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $79.3 million in Q4 2024, with the low at $29.5 million in Q4 2023.
  • Average Total Non-Current Liabilities over 3 years is $58.1 million, with a median of $59.8 million recorded in 2025.
  • The sharpest move saw Total Non-Current Liabilities soared 168.66% in 2024, then fell 16.52% in 2025.
  • Over 3 years, Total Non-Current Liabilities stood at $29.5 million in 2023, then skyrocketed by 168.66% to $79.3 million in 2024, then dropped by 16.52% to $66.2 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $66.2 million, $62.2 million, and $57.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.